Valorisation

Dissémination

A ce jour, le programme HEMODIAG 2020 a permis un certain nombre de publications scientifiques et de brevets : 

Publications scientifiques

  1. Identification of Anti-tumor Cells Carrying Natural Killer (NK) Cell Antigens in Patients With Hematological Cancers. Krzywinska E, Allende-Vega N, Cornillon A, Vo DN, Cayrefourcq L, Panabieres C, Vilches C, Déchanet-Merville J, Hicheri Y, Rossi JF, Cartron G, Villalba M. EBioMedicine. 2015 Aug 13;2(10):1364-76.
  2. The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism. Allende-Vega N, Krzywinska E, Orecchioni S, Lopez-Royuela N, Reggiani F, Talarico G, Rossi JF, Rossignol R, Hicheri Y, Cartron G, Bertolini F, Villalba M. Oncotarget. 2015 Aug 7;6(22):19228-45.
  3. Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production.Khan AUH, Rathore MG, Allende-Vega N, Vo DN, Belkhala S, Orecchioni S, Talarico G, Bertolini F, Cartron G, Lecellier CH, Villalba M. EBioMedicine. 2015 Nov 26;3:43-53.
  4. Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy. Bret C, Viziteu E, Kassambara A, Moreaux J. Expert Rev Hematol. 2016 Feb 12:1-10.
  5. CD45 Isoform Profile Identifies Natural Killer (NK) Subsets with Differential Activity. Krzywinska E, Cornillon A, Allende-Vega N, Vo DN, Rene C, Lu ZY, Pasero C, Olive D, Fegueux N, Ceballos P, Hicheri Y, Sobecki M, Rossi JF, Cartron G, Villalba M. PLoS One. 2016 Apr 21;11(4):e0150434.
  6. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma. Viziteu E, Klein B, Basbous J, Lin YL, Hirtz C, Gourzones C, Tiers L, Bruyer A, Vincent L, Gandmougin C, Seckinger A, Goldschmidt H, Constantinou A, Pasero P, Hose D, Moreaux J. Leukemia. 2017. Mar 10.
  7. Automated and simplified identification of normal and abnormal plasma cells in multiple myeloma by flow cytometry. E Alaterre, S Raimbault, JM Garcia, T Reme, G Requirand, B Klein, J Moreaux. Cytometry B. 2017. Sept 2. 
  8. CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma. E Alaterre, S Raimbault, H Goldschmidt, S Bouhya, G Requirand, N Robert, S Boireau, A Seckinger, D Hose, B Klein, J Moreaux. Oncotarget. 2017 Oct 30;8(58):98931-98944. 
  9. Changes in metabolism affect expression of ABC transporters through ERK5 and depending on p53 status. Belkahla S, Haq Khan AU, Gitenay D, Alexia C, Gondeau C, Vo DN, Orecchioni S, Talarico G, Bertolini F, Cartron G, Hernandez J, Daujat-Chavanieu M, Allende-Vega N, Gonzalez MV. Oncotarget. 2017 Dec 14;9(1):1114-1129.
  10. DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. Bruyer A, Maes K,  Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J. British journal of cancer. 2018 Apr;118(8):1062-1073.
  11. An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy. Szablewski V, Bret C, Kassambara A, Devin J, Cartron G, Costes-Martineau V, Moreaux J. Oncotarget. 2018 Apr 10;9(27):19079-19099.
  12. Mitochondrial Complex I activity signals antioxidant response through ERK5. Khan AUH, Allende-Vega N, Gitenay D, Garaude J, Vo DN, Belkhala S, Gerbal-Chaloin S, Gondeau C, Daujat-Chavanieu M, Delettre C, Orecchioni S, Talarico G, Bertolini F, Anel A, Cuezva JM, Enriquez JA, Cartron G, Lecellier CH, Hernandez J, Villalba M. Sci Rep. 2018 May 9;8(1):7420.  

Brevets

  1. Methods and pharmaceutical compositions for the treatment of multiple myeloma. EP16305176. 2016.
  2. Methods using a marker of multiple myeloma. EP16305682. 2016.
  3. Method for the prognosis of multiple myeloma. EP16305651. 2016.
  4. Detection of minimal residual disease in multiple myeloma. FR1654514. 2016.
  5. Method for the in vitro prognosis of individuals having Multiple Myeloma and method for the treatment thereof. EP16306436.3. 2016.
  6. Prognosis method of Multiple Myeloma. EP17306503.8. 2017.
  7. Methods for the in vitro determination of the outcome and for the treatment of individuals having multiple myeloma. BR76264. 2017.

Communications

  1. Rôle de l’exposition professionnelle aux pesticides dans le pronostic des Lymphomes Diffus à Grandes Cellules B. Lamure S, Baldi I, Aquereburu Q, Quittet P, Tchernonog E, Paul F, Jourdan E, Agathe Waultier, Defez C, Sanhes L, Burcheri S, Donadio D, Exbrayat C, Saad A, Labourey JL, Carles C, Cartron G, Fabbro-Peray P. Oral, Congrès de la Société Française d’Hématologie (SFH), Paris, 2018.
  2. Influence de la cachexie sur la qualité de vie au cours d’une hémopathie lymphoïde : résultats préliminaires issus de la cohorte HémoDiag. Mallard J, Vincent L, Baudinet C, Paul F, Tchernonog E, Lamure S, Gagez AL, Gehlkopf E, Kanouni T, Quittet P, Navarro R, Hicheri Y, Ceballos P, Fegueux N, Herbinet A, Bernard PL, Cartron G. Poster Congrès de la Société Française d’Hématologie (SFH), Paris, 2018.
  3. Lymphome de Hodgkin réfractaire ou en rechute à haut risque ou de risque intermédiaire : une étude rétrospective sur dix ans. Gehlkopf E, Tchernonog E, Gagez AL, Cartron G, Quittet P. Poster Congrès de la Société Française d’Hématologie (SFH), Paris, 2018.
  4. Occupational exposure to pesticides and prognosis of diffuse large B-cell lymphoma: A cohort study. Sylvain Lamure, Camille Carles, Quam Aquereburu, Philippe Quittet, Emmanuelle Tchernonog, Franciane Paul, Eric Jourdan, Agathe Waultier, Christine Defez, Laurence Sanhes, Sara Burcheri, Daniel Donadio, Carole Exbrayat, Alain Saad, Jean-Luc Labourey, Isabelle Baldi, Guillaume Cartron, Pascale Fabbro-Peray. Poster, Congrès Américain de la société d’oncologie Clinique (ASCO), Chicago, 2018.